2013-10-03 16:44:19 - MolMed S.p.A. will present further data on the efficacy of the investigational drug NGR-hTNF in soft tissues sarcomas tomorrow at the European Cancer Congress.
MolMed S.p.A. (MLM.MI) will present further data on the efficacy of its investigational drug NGR-hTNF in combination with doxorubicin in soft tissue sarcomas, tomorrow at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) taking place in Amsterdam (The Netherlands) from September 27th to October 1st 2013.
Dr Emanuela Palmerini from the Istituto ortopedico Rizzoli (Bologna) will give an oral presentation titled “NGR-hTNF given at low dose or high dose with or without doxorubicin in soft-tissue sarcomas” at 9:12 of Tuesday, October the 1st 2013 in the section “Sarcomas: soft tissues and bones”.
New data disclosed at the congress will be announced in separate press releases during the meeting.
Randomized Phase II study of NGR-hTNF in soft tissue sarcomas
This four-arm trial was designed to select the
best NGR-hTNF regimen for patients with sarcomas. The primary aim of achieving a doubled three-month progression-free rate (40% vs 20%) was met by the combination of low-dose intensified NGR-hTNF (0.8 μg/sqm weekly) with doxorubicin, after both the first and the second trial stages.
Preliminary data presented in June at the 49th annual meeting of the American Society of Clinical Oncology (ASCO) also show that the superiority of this regimen over the other ones in terms of progression-free survival (with a three-fold increased median duration) translated into an analogous advantage in terms of overall survival (with a two-fold increased median time).
NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the tumour mass. NGR-hTNF is being investigated in a large clinical program, including a Phase III trial in malignant pleural mesothelioma and Phase II trials in six indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas.
MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company’s shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI).